Sign in
CompletedPhase 1/2

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Key facts

Who runs it
ModernaTX, Inc.
Where
Corvallis, Edmond, Fort Collins, Gaithersburg, Hatboro, Hollywood, Lakewood, Las Vegas, Long Beach, Miami, Moore, Myrtle Beach, Norcross, Omaha, Rockville, Springfield, Springville, St Louis, Tampa, Town and Country, and Vestal, United StatesSee the 22 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
698 people enrolled
Started
27 Mar 2023
Ended
20 Nov 2023
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • mRNA-1011.1
  • mRNA-1011.2
  • mRNA-1012.1
  • mRNA-1010
  • mRNA-1010.2
  • mRNA-1010.3
Record updated
3 February 2025

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Body mass index of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding

Who cannot take part

  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1
  • Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to the Randomization Visit (for glucocorticosteroids ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed
  • Participant has received or plans to receive any licensed or authorized vaccine, including COVID-19 vaccines, ≤28 days prior to the study injection (Day 1) or plans to receive a licensed or authorized vaccine within 28 days after the study injection
  • Participant has received a seasonal influenza vaccine or any other influenza vaccine within 180 days prior to the Randomization Visit
  • Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to the Randomization Visit
  • Participant has had close contact to someone with or been diagnosed themselves with respiratory syncytial virus or SARS-CoV-2 infection as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to the Randomization Visit
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Randomization Visit or plans to donate blood products during the study; Note: Other inclusion/exclusion criteria may apply
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results

Where in United States

  • The Corvallis Clinic, PCCorvallis, United States
  • Tekton ResearchEdmond, United States
  • Tekton ResearchFort Collins, United States
  • CenExel CBHGaithersburg, United States
  • Hatboro Medical Associates/CCT ResearchHatboro, United States
  • CenExel RCAHollywood, United States
  • Critical Care, Pulmonary and Sleep Associates / CCT ResearchLakewood, United States
  • Long Beach Research InstituteLakewood, United States
  • Healor Primary CareLas Vegas, United States
  • Long Beach Clinical TrialsLong Beach, United States
  • Suncoast Research Associates, LLCMiami, United States
  • Tekton ResearchMoore, United States
  • Trial Management Associates, LLCMyrtle Beach, United States
  • Georgia Clinic / CCT ResearchNorcross, United States
  • Meridian Clinical Research, LLCOmaha, United States
  • DelRicht ResearchRockville, United States
  • DelRicht ResearchSpringfield, United States
  • Springville Dermatology CCT ResearchSpringville, United States
  • Sundance Clinical Research, LLCSt Louis, United States
  • CenExel FCRTampa, United States
  • DelRicht ResearchTown and Country, United States
  • Meridian Clinical Research, LLCVestal, United States

About the trial

What the trial wants to find out

The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.

The 7 groups in the trial

  • mRNA-1011.1Treatment being tested

    Participants will receive mRNA-1011.1 by intramuscular (IM) injection on Day 1.

  • mRNA-1011.2Treatment being tested

    Participants will receive mRNA-1011.2 by IM injection on Day 1.

  • mRNA-1012.1 Dose Level ATreatment being tested

    Participants will receive mRNA-1012.1 at dose level A by IM injection on Day 1.

    Treatment: mRNA-1012.1

  • mRNA-1012.1 Dose Level BTreatment being tested

    Participants will receive mRNA-1012.1 at dose level B by IM injection on Day 1.

    Treatment: mRNA-1012.1

  • mRNA-1010Existing treatment, for comparison

    Participants will receive mRNA-1010 by IM injection on Day 1.

  • mRNA-1010.2Existing treatment, for comparison

    Participants will receive mRNA-1010.2 by IM injection on Day 1.

  • mRNA-1010.3Existing treatment, for comparison

    Participants will receive mRNA-1010.3 by IM injection on Day 1.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
Publications
Record updated
3 February 2025